Differential expression and function of alternative splicing variants of human liver X receptor α

Kaori Endo-Umeda, Shigeyuki Uno, Ko Fujimori, Yoshikazu Naito, Koichi Saito, Kenji Yamagishi, Yangsik Jeong, Hiroyuki Miyachi, Hiroaki Tokiwa, Sachiko Yamada, Makoto Makishima

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The liver X receptor α (LXRα) is a nuclear receptor that is involved in regulation of lipid metabolism, cellular proliferation and apoptosis, and immunity. In this report, we characterize three human LXRα isoforms with variation in the ligand-binding domain (LBD). While examining the expression of LXRα3, which lacks 60 amino acids within the LBD, we identified two novel transcripts that encode LXRα-LBD variants (LXRα4 and LXRα5). LXRα4 has an insertion of 64 amino acids in helix 4/5, and LXRα5 lacks the C-terminal helices 7 to 12 due to a termination codon in an additional exon that encodes an intron in the LXRα1 mRNA. LXRα3, LXRα4, and LXRα5 were expressed at lower levels compared with LXRα1 in many human tissues and cell lines. We also observed weak expression of LXRα3 and LXRα4 in several tissues of mice. LXR ligand treatment induced differential regulation of LXRα isoform mRNA expression in a cell type-dependent manner. Whereas LXRα3 had no effect, LXRα4 has weak transactivation, retinoid X receptor (RXR) heterodimerization, and coactivator recruitment activities. LXRα5 interacted with a corepressor in a ligand-independent manner and inhibited LXRα1 transactivation and target gene expression when overexpressed. Combination of LXRα5 cotransfection and LXRα antagonist treatment produced additive effects on the inhibition of ligand-dependent LXRα1 activation. We constructed structural models of the LXRα4-LBD and its complexes with ligand, RXR-LBD, and coactivator peptide. The models showed that the insertion in the LBD can be predicted to disrupt RXR heterodimerization. Regulation of LXRα pre-mRNA splicing may be involved in the pathogenesis of LXRα-related diseases.

Original languageEnglish
Pages (from-to)800-810
Number of pages11
JournalMolecular Pharmacology
Volume81
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Alternative Splicing
Ligands
Retinoid X Receptors
Transcriptional Activation
Liver X Receptors
Personnel Selection
RNA Isoforms
Amino Acids
Co-Repressor Proteins
Terminator Codon
Structural Models
RNA Precursors
Cytoplasmic and Nuclear Receptors
Lipid Metabolism
Cellular Immunity
Introns
Exons
Protein Isoforms
Cell Proliferation
Apoptosis

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Endo-Umeda, K., Uno, S., Fujimori, K., Naito, Y., Saito, K., Yamagishi, K., ... Makishima, M. (2012). Differential expression and function of alternative splicing variants of human liver X receptor α. Molecular Pharmacology, 81(6), 800-810. https://doi.org/10.1124/mol.111.077206

Differential expression and function of alternative splicing variants of human liver X receptor α. / Endo-Umeda, Kaori; Uno, Shigeyuki; Fujimori, Ko; Naito, Yoshikazu; Saito, Koichi; Yamagishi, Kenji; Jeong, Yangsik; Miyachi, Hiroyuki; Tokiwa, Hiroaki; Yamada, Sachiko; Makishima, Makoto.

In: Molecular Pharmacology, Vol. 81, No. 6, 06.2012, p. 800-810.

Research output: Contribution to journalArticle

Endo-Umeda, K, Uno, S, Fujimori, K, Naito, Y, Saito, K, Yamagishi, K, Jeong, Y, Miyachi, H, Tokiwa, H, Yamada, S & Makishima, M 2012, 'Differential expression and function of alternative splicing variants of human liver X receptor α', Molecular Pharmacology, vol. 81, no. 6, pp. 800-810. https://doi.org/10.1124/mol.111.077206
Endo-Umeda, Kaori ; Uno, Shigeyuki ; Fujimori, Ko ; Naito, Yoshikazu ; Saito, Koichi ; Yamagishi, Kenji ; Jeong, Yangsik ; Miyachi, Hiroyuki ; Tokiwa, Hiroaki ; Yamada, Sachiko ; Makishima, Makoto. / Differential expression and function of alternative splicing variants of human liver X receptor α. In: Molecular Pharmacology. 2012 ; Vol. 81, No. 6. pp. 800-810.
@article{90de4c09abe844748680187220da1a84,
title = "Differential expression and function of alternative splicing variants of human liver X receptor α",
abstract = "The liver X receptor α (LXRα) is a nuclear receptor that is involved in regulation of lipid metabolism, cellular proliferation and apoptosis, and immunity. In this report, we characterize three human LXRα isoforms with variation in the ligand-binding domain (LBD). While examining the expression of LXRα3, which lacks 60 amino acids within the LBD, we identified two novel transcripts that encode LXRα-LBD variants (LXRα4 and LXRα5). LXRα4 has an insertion of 64 amino acids in helix 4/5, and LXRα5 lacks the C-terminal helices 7 to 12 due to a termination codon in an additional exon that encodes an intron in the LXRα1 mRNA. LXRα3, LXRα4, and LXRα5 were expressed at lower levels compared with LXRα1 in many human tissues and cell lines. We also observed weak expression of LXRα3 and LXRα4 in several tissues of mice. LXR ligand treatment induced differential regulation of LXRα isoform mRNA expression in a cell type-dependent manner. Whereas LXRα3 had no effect, LXRα4 has weak transactivation, retinoid X receptor (RXR) heterodimerization, and coactivator recruitment activities. LXRα5 interacted with a corepressor in a ligand-independent manner and inhibited LXRα1 transactivation and target gene expression when overexpressed. Combination of LXRα5 cotransfection and LXRα antagonist treatment produced additive effects on the inhibition of ligand-dependent LXRα1 activation. We constructed structural models of the LXRα4-LBD and its complexes with ligand, RXR-LBD, and coactivator peptide. The models showed that the insertion in the LBD can be predicted to disrupt RXR heterodimerization. Regulation of LXRα pre-mRNA splicing may be involved in the pathogenesis of LXRα-related diseases.",
author = "Kaori Endo-Umeda and Shigeyuki Uno and Ko Fujimori and Yoshikazu Naito and Koichi Saito and Kenji Yamagishi and Yangsik Jeong and Hiroyuki Miyachi and Hiroaki Tokiwa and Sachiko Yamada and Makoto Makishima",
year = "2012",
month = "6",
doi = "10.1124/mol.111.077206",
language = "English",
volume = "81",
pages = "800--810",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Differential expression and function of alternative splicing variants of human liver X receptor α

AU - Endo-Umeda, Kaori

AU - Uno, Shigeyuki

AU - Fujimori, Ko

AU - Naito, Yoshikazu

AU - Saito, Koichi

AU - Yamagishi, Kenji

AU - Jeong, Yangsik

AU - Miyachi, Hiroyuki

AU - Tokiwa, Hiroaki

AU - Yamada, Sachiko

AU - Makishima, Makoto

PY - 2012/6

Y1 - 2012/6

N2 - The liver X receptor α (LXRα) is a nuclear receptor that is involved in regulation of lipid metabolism, cellular proliferation and apoptosis, and immunity. In this report, we characterize three human LXRα isoforms with variation in the ligand-binding domain (LBD). While examining the expression of LXRα3, which lacks 60 amino acids within the LBD, we identified two novel transcripts that encode LXRα-LBD variants (LXRα4 and LXRα5). LXRα4 has an insertion of 64 amino acids in helix 4/5, and LXRα5 lacks the C-terminal helices 7 to 12 due to a termination codon in an additional exon that encodes an intron in the LXRα1 mRNA. LXRα3, LXRα4, and LXRα5 were expressed at lower levels compared with LXRα1 in many human tissues and cell lines. We also observed weak expression of LXRα3 and LXRα4 in several tissues of mice. LXR ligand treatment induced differential regulation of LXRα isoform mRNA expression in a cell type-dependent manner. Whereas LXRα3 had no effect, LXRα4 has weak transactivation, retinoid X receptor (RXR) heterodimerization, and coactivator recruitment activities. LXRα5 interacted with a corepressor in a ligand-independent manner and inhibited LXRα1 transactivation and target gene expression when overexpressed. Combination of LXRα5 cotransfection and LXRα antagonist treatment produced additive effects on the inhibition of ligand-dependent LXRα1 activation. We constructed structural models of the LXRα4-LBD and its complexes with ligand, RXR-LBD, and coactivator peptide. The models showed that the insertion in the LBD can be predicted to disrupt RXR heterodimerization. Regulation of LXRα pre-mRNA splicing may be involved in the pathogenesis of LXRα-related diseases.

AB - The liver X receptor α (LXRα) is a nuclear receptor that is involved in regulation of lipid metabolism, cellular proliferation and apoptosis, and immunity. In this report, we characterize three human LXRα isoforms with variation in the ligand-binding domain (LBD). While examining the expression of LXRα3, which lacks 60 amino acids within the LBD, we identified two novel transcripts that encode LXRα-LBD variants (LXRα4 and LXRα5). LXRα4 has an insertion of 64 amino acids in helix 4/5, and LXRα5 lacks the C-terminal helices 7 to 12 due to a termination codon in an additional exon that encodes an intron in the LXRα1 mRNA. LXRα3, LXRα4, and LXRα5 were expressed at lower levels compared with LXRα1 in many human tissues and cell lines. We also observed weak expression of LXRα3 and LXRα4 in several tissues of mice. LXR ligand treatment induced differential regulation of LXRα isoform mRNA expression in a cell type-dependent manner. Whereas LXRα3 had no effect, LXRα4 has weak transactivation, retinoid X receptor (RXR) heterodimerization, and coactivator recruitment activities. LXRα5 interacted with a corepressor in a ligand-independent manner and inhibited LXRα1 transactivation and target gene expression when overexpressed. Combination of LXRα5 cotransfection and LXRα antagonist treatment produced additive effects on the inhibition of ligand-dependent LXRα1 activation. We constructed structural models of the LXRα4-LBD and its complexes with ligand, RXR-LBD, and coactivator peptide. The models showed that the insertion in the LBD can be predicted to disrupt RXR heterodimerization. Regulation of LXRα pre-mRNA splicing may be involved in the pathogenesis of LXRα-related diseases.

UR - http://www.scopus.com/inward/record.url?scp=84861417926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861417926&partnerID=8YFLogxK

U2 - 10.1124/mol.111.077206

DO - 10.1124/mol.111.077206

M3 - Article

C2 - 22399489

AN - SCOPUS:84861417926

VL - 81

SP - 800

EP - 810

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -